Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2026-02-17 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release titled 'VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY'. It explicitly references articles L.233-8 II of the French Commercial Code and 223-16 of the AMF General Regulation, which mandate the disclosure of the total number of shares and voting rights. This type of regulatory disclosure regarding share capital and voting rights is classified under the DVA (Declaration of Voting Results & Voting Rights Announcements) category.
2026-02-17 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Regulatory Filings Classification · 95% confidence The document is a monthly disclosure from Nanobiotix regarding the total number of shares and voting rights, as required by French regulatory authorities (AMF). This type of filing is a standard regulatory disclosure of capital structure and voting rights, which falls under the 'Regulatory Filings' category as it does not represent a specific corporate event like a dividend, share buyback, or major shareholding notification, but rather a routine compliance update.
2026-02-17 French
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is a formal notification of a change in shareholding levels (crossing thresholds) by The Goldman Sachs Group, Inc. regarding the company NANOBIOTIX. It explicitly references 'Déclaration de franchissement de seuils' (Declaration of crossing thresholds) and cites Article L. 233-7 of the French Commercial Code, which is the standard regulatory requirement for major shareholding notifications. This fits the definition of a Major Shareholding Notification (MRQ).
2026-02-02 French
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the AMF (Autorité des marchés financiers) regarding a 'Déclaration de franchissement de seuils' (Declaration of crossing thresholds). It details that The Goldman Sachs Group, Inc. has crossed the 5% ownership threshold in the company NANOBIOTIX. This falls under the definition of a Major Shareholding Notification (MRQ).
2026-02-02 French
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuils' (threshold crossing declaration). It details that The Goldman Sachs Group, Inc. has crossed below the 5% ownership threshold of the company NANOBIOTIX. This is a standard regulatory notification for major shareholding changes.
2026-01-27 French
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuils' (threshold crossing declaration). It details that The Goldman Sachs Group, Inc. has crossed the 5% ownership threshold in the company NANOBIOTIX. This falls directly under the definition of a Major Shareholding Notification.
2026-01-26 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.